scholarly journals Lambda Interferon Restructures the Nasal Microbiome and Increases Susceptibility to Staphylococcus aureus Superinfection

mBio ◽  
2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Paul J. Planet ◽  
Dane Parker ◽  
Taylor S. Cohen ◽  
Hannah Smith ◽  
Justinne D. Leon ◽  
...  

ABSTRACT Much of the morbidity and mortality associated with influenza virus respiratory infection is due to bacterial coinfection with pathogens that colonize the upper respiratory tract such as methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae . A major component of the immune response to influenza virus is the production of type I and III interferons. Here we show that the immune response to infection with influenza virus causes an increase and restructuring of the upper respiratory microbiota in wild-type (WT) mice but not in Il28r −/− mutant mice lacking the receptor for type III interferon. Mice lacking the IL-28 receptor fail to induce STAT1 phosphorylation and expression of its regulator, SOCS1. Il28r −/− mutant mice have increased expression of interleukin-22 (IL-22), as well as Ngal and RegIIIγ, in the nasal cavity, the source of organisms that would be aspirated to cause pneumonia. Proteomic analysis reveals changes in several cytoskeletal proteins that contribute to barrier function in the nasal epithelium that may contribute to the effects of IL-28 signaling on the microbiota. The importance of the effects of IL-28 signaling in the pathogenesis of MRSA pneumonia after influenza virus infection was confirmed by showing that WT mice nasally colonized before or after influenza virus infection had significantly higher levels of infection in the upper airways, as well as significantly greater susceptibility to MRSA pneumonia than Il28r −/− mutant mice did. Our results suggest that activation of the type III interferon in response to influenza virus infection has a major effect in expanding the upper airway microbiome and increasing susceptibility to lower respiratory tract infection. IMPORTANCE S. aureus and influenza virus are important respiratory pathogens, and coinfection with these organisms is associated with significant morbidity and mortality. The ability of influenza virus to increase susceptibility to S. aureus infection is less well understood. We show here that influenza virus leads to a change in the upper airway microbiome in a type III interferon-dependent manner. Mice lacking the type III interferon receptor have altered STAT1 and IL-22 signaling. In coinfection studies, mice without the type III interferon receptor had significantly less nasal S. aureus colonization and subsequent pneumonia than infected WT mice did. This work demonstrates that type III interferons induced by influenza virus contribute to nasal colonization and pneumonia due to S. aureus superinfection.

1949 ◽  
Vol 47 (4) ◽  
pp. 434-448 ◽  
Author(s):  
C. H. Stuart-Harris ◽  
Joan Laird ◽  
D. A. Tyrrell ◽  
Margaret H. Kelsall ◽  
Zena C. Franks ◽  
...  

1.The results are reported of a study cases of pneumonia, of upper respiratory indection and of family contacts of cases of pneumoia for evidence of influenza-virus infection between October 1947 and April 1949.2. During an inter-epidemic period in relation to influenza, two sporadic cases of influenza-virus A infection were detected, one in a case of pneumo-coccal pneumonia and the other in a family contact of a case of pneumonia. These were the only instances of virus infection detected amoung 158 individuals including seventy-eight cases of pneumonia.3. The epidemic of influenza from February to April 1949 was associated with an increase in number of notified cases of pneumonia, particularly in those over 45 years of age compared with the notifications in 1948. Deaths from pneumonia also increased, particularly in those of 65years or over.4. During the period of influenza prevalence, direct tests of specimens in eggs and serological tests gave positive evidence of influenza prevalence, direct tests of specimens in eggs and serological tests gave positve evidence of influenza virus A infection in many instances. Twenty-six of forty-one cases of upper respiratory infection between February and April 1949 were positive for influenza A and one was a case of influenza B.5. Eifgteen of fifty-five cases of pneumococcal and staphyococcal pneumoniaccal and staphylococcal pneumonia, eight of fifteen cases of bronchitis, one of two cases of bronchiectasis and four of six cases of congestive heart failure gave serological or cultural evidence of influenza virus A infection during the period of February to April 1949.6. The mechanism of influenza-virus infection in relation to bacterial infection of the lower respiratory tract is discussed.


2017 ◽  
Vol 2 (12) ◽  
pp. eaam6970 ◽  
Author(s):  
Angela Pizzolla ◽  
Thi H. O. Nguyen ◽  
Jeffrey M. Smith ◽  
Andrew G. Brooks ◽  
Katherine Kedzierska ◽  
...  

2001 ◽  
Vol 8 (3) ◽  
pp. 593-597 ◽  
Author(s):  
Tetsuji Hori ◽  
Junko Kiyoshima ◽  
Kan Shida ◽  
Hisako Yasui

ABSTRACT In mice administered Lactobacillus casei strain Shirota (LcS) intranasally, potent induction of interleukin 12, gamma interferon, and tumor necrosis factor alpha, which play a very important role in excluding influenza virus (IFV), was evident in mediastinal lymph node cells. In this model of upper respiratory IFV infection, the titers of virus in the nasal wash of mice inoculated with 200 μg of LcS for three consecutive days (LcS 200 group) before infection were significantly (P < 0.01) lower than those of mice not inoculated with LcS (control group) (100.9 ± 0.6 versus 102.1 ± 1.0). The IFV titer was decreased to about 1/10 of the control level. Using this infection model with modifications, we investigated whether the survival rate of mice was increased by intranasal administration of LcS. The survival rate of the mice in the LcS 200 group was significantly (P < 0.05) greater than that of the mice in the control group (69% versus 15%). It seems that the decrease in the titer of virus in the upper respiratory tract to 1/10 of the control level was important in preventing death. These findings suggest that intranasal administration of LcS enhances cellular immunity in the respiratory tract and protects against influenza virus infection.


2017 ◽  
Vol 91 (14) ◽  
Author(s):  
Karen Ivinson ◽  
Georgia Deliyannis ◽  
Leanne McNabb ◽  
Lara Grollo ◽  
Brad Gilbertson ◽  
...  

ABSTRACT It is possible to model the progression of influenza virus from the upper respiratory tract to the lower respiratory tract in the mouse using viral inoculum delivered in a restricted manner to the nose. In this model, infection with the A/Udorn/307/72 (Udorn) strain of virus results ultimately in high viral titers in both the trachea and lungs. In contrast, the A/Puerto Rico/8/34 (PR8) strain causes an infection that is almost entirely limited to the nasal passages. The factors that govern the progression of virus down the respiratory tract are not well understood. Here, we show that, while PR8 virus grows to high titers in the nose, an inhibitor present in the saliva blocks further progression of infection to the trachea and lungs and renders an otherwise lethal dose of virus completely asymptomatic. In vitro, the salivary inhibitor was capable of potent neutralization of PR8 virus and an additional 20 strains of type A virus and two type B strains that were tested. The exceptions were Udorn virus and the closely related H3N2 strains A/Port Chalmers/1/73 and A/Victoria/3/75. Characterization of the salivary inhibitor showed it to be independent of sialic acid and other carbohydrates for its function. This and other biochemical properties, together with its virus strain specificity and in vivo function, indicate that the mouse salivary inhibitor is a previously undescribed innate inhibitory molecule that may have evolved to provide pulmonary protection of the species from fatal influenza virus infection. IMPORTANCE Influenza A virus occasionally jumps from aquatic birds, its natural host, into mammals to cause outbreaks of varying severity, including pandemics in humans. Despite the laboratory mouse being used as a model to study influenza virus pathogenesis, natural outbreaks of influenza have not been reported in the species. Here, we shed light on one mechanism that might allow mice to be protected from influenza in the wild. We show that virus deposited in the mouse upper respiratory tract will not progress to the lower respiratory tract due to the presence of a potent inhibitor of the virus in saliva. Containing inhibitor-sensitive virus to the upper respiratory tract renders an otherwise lethal infection subclinical. This knowledge sheds light on how natural inhibitors may have evolved to improve survival in this species.


Sign in / Sign up

Export Citation Format

Share Document